Drug intelligence / Profile preview

SUIVAC PRRS-IN

Development stage: Unknown
Lead developer: Dyntec
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

SUIVAC PRRS-IN is an inactivated veterinary vaccine developed by Dyntec for the active immunization of pigs against Porcine Reproductive and Respiratory Syndrome (PRRS). The vaccine contains inactivated Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) antigens, typically formulated with an oil adjuvant to enhance the immune response. It is indicated for use in sows and gilts to prevent reproductive disorders and in piglets to reduce respiratory symptoms associated with PRRSV infection. The vaccine is administered via intramuscular injection and is part of Dyntec's Suivac range of swine vaccines.

Brand names: SUIVAC PRRS-IN
Other names: SUIVAC PRRS inact

Targets

PRRSV antigen (Porcine reproductive and respiratory syndrome virus antigen)

Beyond the preview

Go deeper on SUIVAC PRRS-IN.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SUIVAC PRRS-IN.

Explore the full profile